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TheobjectiveofthisclinicalstudyistoexaminetheeﬀectsofaChineseherbalmedicineformula(JiaWeiLiuJunZiTang:JWLJZT)
on motor and non-motor symptoms, and on complications of conventional therapy in idiopathic Parkinson’s disease (PD), using
an add-on design. Fifty-ﬁve patients with PD were randomly allocated to receive either Chinese herbal medicine or placebo for
24 weeks. Primary outcome measure was the 39-item Parkinson’s Disease Questionnaire (PDQ-39). Secondary outcome measures
includedtheUniﬁedParkinson’sDiseaseRatingScale(UPDRS),Short-Form-36HealthSurvey(SF-36),GeriatricDepressionScale
(GDS),homediaries,and arangeofcategory ratingscales. JWLJZT resulted inasigniﬁcant improvement intheUPDRSIVCwhen
compared with placebo at 12 weeks (P = .039) and 24 weeks (P = .034). In addition, patients in the Chinese herbal medicine group
also showed signiﬁcant improvement in PDQ-39 communication scores at 12 weeks (P = .024) and 24 weeks (P = .047) when
compared with the placebo group. There were no signiﬁcant diﬀerences between treatment and control groups for SF-36 variables,
GDS score or the mean daily “on-oﬀ” time. One case of mild diarrhea was noted in the treatment group. The ﬁndings suggest that
JWLJZT can relieve some non-motor complications of conventional therapy and improve the communication ability in patients
with PD. The results of this pilot study warrant larger multi-center clinical studies to assess long-term eﬃcacy and tolerability of
JWLJZT, and to elucidate the mechanisms by which it aﬀects PD function.
1.Introduction
Parkinson’s disease (PD) is a neurodegenerative disease
with prominent motor impairments that include resting
tremor, rigidity, bradykinesia and postural abnormality.
Epidemiological studies show that the prevalence of PD in
industrialized countries is usually estimated at 0.3% of the
whole population and at ∼1% in people over 60 years of age
[1]. A previous study of the Chinese population in Hong
Kong reported that the prevalence among those aged ≥55
years was 0.5% [2].
Despite various advances in the understanding of PD,
pharmacological treatment of PD by Western medicine
is mainly for symptom management. Among diﬀerent
pharmacological treatments, levodopa remains the most
eﬃcacious and is still the mainstay of therapy [3]. However,
long-term use of levodopa can cause disabling motor
complications, particularly dyskinesias and motor ﬂuctua-
tions, which limit its usefulness [4]. Both of these motor
c o m p l i c a t i o n sh a v eb e e nf o u n dt oo c c u ri n∼40 and
70% of patients after 5 years and 15 years of levodopa
treatment, respectively, [5, 6]. Moreover, combined with
motor abnormality, many non-motor aspects of PD can
signiﬁcantly aﬀect patients’ quality of life by causing such
problems as autonomic dysfunction, constipation, nausea,
sleep disruption, pain, excessive daytime sleepiness and
mood disturbances. These problems often do not respond
to and may even be worsened by conventional medical
treatments.
In view of the undesirable long-term side eﬀects of
Western medicine, many patients seek alternative treatment
for PD. Traditional Chinese medicine (TCM) has been
used for centuries to treat conditions such as trembling of
hands and shaking of head that correspond to the modern2 Evidence-Based Complementary and Alternative Medicine
term “PD”. Up to the present, Chinese herbal medicine
remains very popular for management of PD in Asian
countries such as China, Korea and Japan. In a study done
by Rajendran et al., it was observed that 40% of patients
with PD use at least one form of alternative therapy [7].
Herbal medicine is one of the three most popular forms
of alternative therapy adopted by PD patients. However,
there are very few rigorously designed clinical trials that
examine the eﬃcacy of TCM in PD [8]. One study from
Japan evaluated the role of Chinese herbal medicine in
patients with antipsychotic-induced Parkinsonism [9]. With
the use of a standard 10-herb formula, the investigators
demonstrated a signiﬁcant reduction in tremor in patients.
Unlike Western medicine, TCM diagnoses of PD fall into
diﬀerent categories according to the patient’s fundamental
constitution. According to TCM theory, PD is a condition
that represents a depletion of energy, especially in the
spleen and stomach. Herbal drugs have therefore been used
in the treatment of PD under the general guideline of
“strengthening the spleen and regulating the stomach”. “Jia
W e iL i uJ u nZ iT a n g ” (JWLJZT) is an ancient formulation
developed by a TCM doctor Zhang Lu in 1695 AD, with
the speciﬁc function of tonifying the energy (Qi)o fs p l e e n
and stomach; it has been used to treat symptoms that are
now deﬁned as PD [10]. In this study, we determined the
eﬀect of this formulation of Chinese herbal medicine on the
symptoms and quality of life of patients with idiopathic PD.
2. Methods
2.1. Patients. All idiopathic PD patients (aged 20–80 years)
who presented to the Mr and Mrs Chan Hon Yin Modern
Chinese Medicine Research and Service Centre of the Queen
Elizabeth Hospital, Hong Kong, were screened for eligibility.
Diagnosis of idiopathic PD was based on UK Brain Bank
criteria [11]. Inclusion criteria were Hoehn & Yahr (H&Y)
stage <5, optimal and stable levodopa treatment for at least
1 month prior to beginning the study, presence of motor
ﬂuctuations and dyskinesias during the center visits, and
stablemedical condition thatwould enablethe participant to
ﬁnish the treatment protocol. Even when a patient’s medical
condition needed adaptation, that is, due to occurrence
of other mild illnesses but not severe concurrent illness,
such as active cardiac, liver, renal or neoplastic disease, this
adaptation did not lead to exclusion.
Patients with atypical or secondary Parkinsonism, pro-
nounced clinically relevant cognitive impairment (Mini
Mental State Examination score <24), severe concurrent
illness or history of psychotic illness were excluded. Women
who were pregnant, lactating or not maintaining proper
contraception were not eligible. Concomitant use of Chinese
medicines other than the study drug was not allowed. After
assessmentbyaneurologist,eligiblepatientswereassessedby
a TCM practitioner to ensure their eligibility for the current
TCM formulation according to TCM theories. Patients had
to be diagnosed with the TCM syndrome of “asthenia of the
spleen and stomach” before randomization [12]. Informed
written consent was obtained from all eligible patients, and
the study protocol was approved by the Ethics Committee
of the Hong Kong Baptist University’s Institutional Review
Board (approval code: HASC/05-06/12).
2.2. Trial Design. This was a prospective, randomized
double-blinded placebo-controlled study. Patients were ran-
domly allocated to receive either 24 weeks of active herbal
formulation or placebo with each dose of their levodopa
treatment. Stratiﬁed blocked randomization was carried
out by dividing the sample at baseline into participants
with H&Y stages I, II, III or IV, and then carrying out a
blocked randomization within each of these four strata by
a computer-generated list of random numbers. Random-
ization information was kept in a blinded format by an
independent research assistant (S.C.M.) who had provided
the active drugs and placebos. It was kept in a location far
away from the clinic where patients were being assessed.
Emergency envelopes with the randomization code were also
keptwiththeTCMpractitioner(Y.C.L.)attheSchoolofChi-
nese Medicine in Hong Kong Baptist University. The assessor
(W.F.K.) and patients were blinded to treatment allocation
for the duration of the study. Treatment assignments were
not revealed until the study was ﬁnished. The study started
in February 2007 and ﬁnished in June 2008.
2.3. Herbal Preparation. For this study, we used herbal
granules prepared according to the formula of TCM doctor
ZhangLuoftheQing Dynasty(1695).Thisformulaisspeciﬁc
for the TCM syndrome that matches symptoms of PD, and it
is the basis of many over-the-counter patent medicines that
are widely available in Chinese herbal stores throughout the
world. Based on the original recipe for JWLJZT, the herbal
preparation used in this study contained 11 herbs as listed
in Table 1. The production of herbal granules was done by
the GMP plant of Eu Yan Sang Ltd (Hong Kong). Extraction
was done in a single batch to ensure consistent quality. A
mixture of the herbs was extracted with hot water; after that,
theaqueousextractwasconcentrated,spray-driedandputin
sealed opaque aluminum bags. All herbs were obtained from
qualiﬁed suppliers in Hong Kong and authenticated at the
ChineseManufacturersAssociationTestingandCertiﬁcation
Laboratories and the Eu Yan Sang Research and Analysis
Laboratory on the basis of standards speciﬁed in the
Pharmacopoeia of the People’s Republic of China (2005
edition). These tests included macroscopic and microscopic
examination of cross-sections and powders, chemical tests,
and/or chromatographic analyses. Contamination screening
for heavy metals, pesticides, and a microbial limit test were
performed to ensure safety for human utilization. A placebo
of similar appearance, size and taste was made using lactose,
citric acid, caramel and Momordica charantia fruits. This was
packed in the same manner as the active herbal medicine in
opaque aluminum bags. All packages were distributed by an
independent researcher in another room after the patients’
visits. Patients were instructed to dissolve the granules in
each package in hot water and drink once daily.
2.4. Assessments. Baseline evaluation was performed before
randomization and comprised: the 39-item Parkinson’s
Disease Questionnaire (PDQ-39 including all dimensionsEvidence-Based Complementary and Alternative Medicine 3
Table 1: Herbal preparation
Chinese name Pharmaceutical name Percentage
Dang shen Dried root of Codonopsis pilosula (Franch.) Nannf. (Fam. Campanulaceae) 13.39
Sheng di Dried root tuber of Rehmannia glutinosa Libosch. (Fam. Scrophulariaceae) 13.39
Fu ling Dried sclerotium of the fungus, Poria cocos (Schw.) Wolf. (Fam. Polyporaceae) 10.71
Gou teng Dried hook-bearing stem branch of Uncaria rhynchophylla (Miq.) Jacks. (Fam. Rubiaceae) 10.71
Bai Zhu Rhizome of Atractylodes macrocephala Koidz. (Fam. Compositae) 8.93
Dang gui Dried root of Angelica sinensis (Oliv) Diels. (Fam. Umbelliferae) 8.93
Fa ban xia Dried tuber of Pinelliae ternate (Thunb.) Breit. (Fam. Araceae) 8.04
Chuan xiong Dried rhizome of Ligusticum chuanxiong Hort. (Fam. Umbelliferae) 8.04
Huai niu xi Dried root of Achyranthes bidentata Bl. (Fam. Amaranthaceae) 8.04
Chen pi Dried pericarp of the ripe fruit of Citrus reticulata Blanco. (Fam. Rutaceae) 5.36
Sheng gan cao Dried root and rhizome of Glycyrrhiza uralensis Fisch. (Fam. Leguminosae) 4.46
andthesingleindex)[13];UniﬁedPDRatingScale(UPDRS)
[14]; Short Form-36 Health Survey (SF-36) [15]; Geriatric
Depression Scale (GDS) [16]; and Deﬁciency of Spenic Qi
Scale (DSQS) [12]. Side eﬀects from conventional treatment,
forexample,mouthdryness,constipation,nausea,insomnia,
palpitation, on-oﬀ phenomenon, dyskinesias and mental
problems, were assessed in a structured interview developed
for this purpose. The home diary was completed by the
patients or their care-givers covering the period from 6
AM till midnight (divided into 30-min intervals) for the
3 days preceding the subsequent visit. For each half-hour
segment, it was recorded whether the patient was “on”, “oﬀ”
or “in bed”. The proportion of “oﬀ” time while awake was
calculated by dividing the total number of “oﬀ”h o u r so v e r3
days by the total number of hours awake. Formal instruction
for the patients to complete the home diary was given during
the ﬁrst visit. Compliance was deﬁned by the use of >70%
of study herbal medicine, and was determined by counting
the returned TCM packages. Adverse events (AEs) were
reported spontaneously by the patient or observed by the
investigator; the severity, outcome and hypothetical cause of
each reported AE were assessed and recorded.
The same TCM practitioner (W.F.K.) also assessed the
patients during each visit based on standard TCM practice,
including inspection, auscultation and olfaction, interroga-
tion, pulse-taking and palpation. Alteration of the study
herbal medications was not allowed during the study period.
Follow-up evaluations were held for all patients at 12
weeks (on treatment) and 24 weeks (end of treatment).
Assessment was carried out in the “on” state, that is, time of
optimal medication eﬀect as deﬁned by the patient. Follow-
up examinations were carried out at similar times of the day
to attenuate eﬀects of motor ﬂuctuations.
2.5. Statistical Analysis. Based on previously published stud-
ies[17,18],asamplesizeof36forthestudywascalculatedto
besuﬃcienttoenabledetectionofareductionintheprimary
outcome measure (PDQ-39 single index) by 11 points with
80% conﬁdence to a signiﬁcance level of 0.05.
All eﬃcacy analyses were performed in the intent-to-
treat (ITT) population, which comprised all randomized
patients who had a baseline measurement and at least one
measurementwhileonthestudydrug.Statisticalanalysiswas
performed using SPSS software version 12 (SPSS, Chicago,
IL). Normality of data was checked by K-S test. For normally
distributed data, independent Student’s t-test was applied to
12weeksand24weeks—baselinediﬀerences,respectively,for
the two groups of patients. Diﬀerences within groups before
and after the 12 and 24 weeks treatment were determined
using paired t-test. For non-normally distributed data, the
Mann-Whitney U-test or Wilcoxon’s rank sum test was
used as appropriate. A P-value ≤.05 was considered to be
statistically signiﬁcant.
3. Results
3.1. Patients. A total of 106 patients with PD were screened,
of which 55 met the inclusive criteria and were random-
ized. Twenty-eight patients were allocated to receive herbal
medicine and 27 to receive placebo. The patient ﬂow and
reasons for exclusion are shown in Figure 1. Eight subjects
were excluded from the analysis because they left the study
before any post-baseline testing. Analysis was performed on
the remaining 47 subjects, 22 in the TCM group and 25
in the placebo group. There were no signiﬁcant diﬀerences
between the two treatment groups with regard to baseline
characteristics (Table 2). A total of 14 (25.5%) patients
withdrew from the trial during the study period: 7 (25%) in
the TCM group and 7 (25.9%) in the placebo group. Twenty-
onepatientsintheTCMgroupand20patientsintheplacebo
group completed the study.
3.2. Treatment Eﬀects within Groups. The mean score of
PDQ-39 single index, total UPDRS and other parameters
with signiﬁcant change are shown in Table 3. TCM therapy
signiﬁcantly reduced the complications of therapy from 4.22
points at baseline to 3.36 points at 12 weeks and 3.22 points
at 24 weeks (UPDRS Part IV; P<. 05). UPDRS Part IVC
(other complications) scores in the TCM group were signiﬁ-
cantly improved from 1.09 to 0.64 points and 0.50 points at
12 and 24 weeks, respectively, (P<. 05). Communications
at 12 and 24 weeks signiﬁcantly worsened in the placebo
group from baseline 23.75 to 30.67 points and 29.67 points,
respectively, (PDQ-39 Communications scale; P<. 05).4 Evidence-Based Complementary and Alternative Medicine
DBS requiring hospitalization × 1
(PDQ-39 = 29.48)
DBS requiring hospitalization × 1
(PDQ-39 = 48.65)
Assessed for
eligibility: n = 106
Excluded: n = 51
Refused to participate (4)
Other reasons (3)
Randomized:
n = 55
Lost to follow-up: n = 6
Analyzed: n = 22 Analyzed: n = 25
Intercurrent disease × 1
(PDQ-39 = 11.72)
Intercurrent disease × 2
(PDQ-39 = 29.06, 29.27)
Analyzed: n = 22(ITT) Analyzed: n = 25(ITT)
Enrollment
Allocation
Follow-up
Follow-up
3 months
Analysis
Analysis
3 months
6 months
6 months
Allocated to Chinese herbal
medicine group: n = 28
Lost to follow-up: n = 2
Refused examination × 1 (PDQ-39 = 21.86)
Refused examination × 1 (PDQ-39 = 16.2)
Intercurrent disease × 1 (PDQ-39 = 14.58)
Diarrhea × 1 (PDQ-39 = 40.47)
Protocol violation × 1 (PDQ-39 = 17.34)
Ful ﬁlling exclusion criteria /not
meeting inclusion criteria (44)
Allocated to control group:
n = 27
Discont.intervention: n = 1 Discont.intervention: n = 5
Disappointment with treatment × 2
(PDQ-39 = 34.22, 25.31)
Without reasons × 2 (PDQ-39 = 2.76, 43.7)
Figure 1: Patients ﬂow. Dropouts are given along with their PDQ-39 summary index score at baseline.Evidence-Based Complementary and Alternative Medicine 5
Table 2: Patient characteristics at baseline.
Parameter TCM group Control group
(n = 22) (n = 25)
Age (years) 64.82 ± 8.88 60.88 ± 9.41
Gender (men/women) 14/8 17/8
Disease duration (years) 5.44 ± 5.26 6.37 ± 4.93
Duration of levodopa
treatment (years) 5.36 ± 5.27 6.12 ± 4.89
Total levodopa daily 405.68 ± 295.80 498.00 ± 313.74
dose (mg)
Baseline scores
H&Y score 2.68 ± 1.09 2.24 ± 0.88
PDQ-39 Single Index 28.96 ± 13.19 29.21 ± 15.44
UPDRS Total 55.45 ± 21.48 48.80 ± 18.92
GDS score 16.18 ± 6.79 15.64 ± 6.28
Daily oﬀ time (%) 16.65 ± 17.59 22.94 ± 19.24
Values given as mean ± SD.
There was no diﬀerence between control group and TCM
group in the items of the SF-36 Health Survey. There were
also no signiﬁcant changes in other parameters including
GDS, DSQS, mean “oﬀ” time, and the structured interview
items in the test and the control groups (Data not shown).
3.3. Group Diﬀerences. Comparisons between the TCM
group and the control group in PDQ-39 single index, total
UPDRS and other parameters with signiﬁcant diﬀerence are
summarized in Table 4. The PDQ-39 Communications score
improved in the TCM group but worsened in the control
group. Group diﬀerences for this scale were signiﬁcant at
both time points (P<. 05). There was no group eﬀect on the
rest of the sections of PDQ-39. TCM reduced complications
of therapy (UPDRS Part IV) more than placebo at 12 weeks
(P = .03) but not at 24 weeks. However, there was a trend
for TCM to improve the UPDRS Part IV score more than
placebo at 24 weeks (P = .09). UPDRS Part IVC (other
complications) score improved signiﬁcantly more with TCM
than with placebo at both time points (P<. 05). There was
no group eﬀect on other parts of UPDRS (data not shown).
For the measures in SF-36, GDS, DSQS, mean “oﬀ”t i m e ,
and the structured interview items, there were no signiﬁcant
diﬀerences between the TCM group and the placebo group
(data not shown).
3.4. Adverse Events. Most patients tolerated the study drug
well. One patient in the TCM group suﬀered from mild
diarrhea. No other adverse eﬀects were reported by patients.
4. Discussion
Despite widespread enthusiasm for TCM among the public,
there is little controlled clinical data on its eﬃcacy. In
this research, we studied the eﬃcacy of an ancient TCM
formulation in treating idiopathic PD in Chinese patients.
This study has various special features. First, while there
are signiﬁcant diﬀerences in the theory between TCM and
conventional Western medicine, we were able to include
patients with a diagnosis conﬁrmed by both Western criteria
ofPD(UKBrainBank)andTCMdiagnosticcriteria[11,12].
This design ensured the inclusion of patients that would
potentially beneﬁt from this herbal medicine. Next, diﬀerent
from many previous studies on TCM treatment of PD [19],
this was a randomized double-blinded placebo-controlled
trial. All herbal medicine and placebos were packaged in
identicalaluminumbagstoassuresatisfactoryblindingofthe
patients and assessors. Moreover, we assessed each patient’s
health-related quality of life in addition to his/her PD
symptoms.
The results of this study showed that JWLJZT,m a d e
from a Chinese herbal decoction, signiﬁcantly reduced
some non-motor complications in patients with PD under
conventional medicine treatment. The major improvement
was reﬂected by the reduction of score in UPDRS IVC which
assessed gastrointestinal disorders, such as anorexia, nausea
and vomiting, sleep disturbances, such as insomnia and
hypersomnolence, and symptomatic orthostasis. In addition
to the UPDRS IVC results, our results showed signiﬁcant
improvement in the whole UPDRS IV in JWLJZT groups
after 12 and 24 weeks of treatment. However, these results
are not conclusive because analysis of the UPDRS IV as three
separate parts showed no signiﬁcant changes in the dyski-
nesias section (UPDRS IVA) nor in the clinical ﬂuctuations
section (UPDRS IVB). Also, there was no signiﬁcant change
in the mean daily “oﬀ”t i m ei nb o t hg r o u p sa sm e a s u r e db y
homediaries,despiteatrendofreductionofmeandaily“oﬀ”
time in JWLJZT groups at 24 weeks (baseline: 16.65 ± 17.59
versus 24 weeks: 13.15 ± 16.58, P = .097). Our results
are supported by the ﬁndings of a previous clinical trial
which assessed the eﬃcacy of another herbal medicine,
“Zhenzhanning”(ZZN),i nP D[ 20]. It was reported that
frequency of nausea, vomiting, anorexia and orthostatic
hypotension of the test group decreased signiﬁcantly more
than in the control group. In addition to this latter study,
other clinical experiments with Chinese herbal medicines
have demonstrated signiﬁcant improvement in non-motor
complications of conventional therapy, including reduced
sleeplessness, vivid dreaming, constipation, dizziness and
fatigue [21–23].
A previous clinical study evaluated the eﬀects of a
prescription similar to ours (six of the herbs present in our
formulationarealsointheirformulation)[24].Hiyamaetal.
assessed the eﬃcacy of Liu Jun Zi Tang (LJZT) in treating PD
patients with clinical ﬂuctuation. It focused on the inﬂuence
of reduced gastric emptying in PD patients which may lead
to ﬂuctuations in the plasma levels of levodopa. As a result,
they used LJZT and levodopa to treat seven PD patients
with motor ﬂuctuations. Assessment included observation
of tremor, rigidity and bradykinesias, the patient’s subjective
scoring scale, absorption of Acetaminophen, and plasma
level of levodopa. Two weeks later, the results showed
that LJZT signiﬁcantly improved patient’s mobility and
percentage of mean daily “on” time. Moreover, frequency of
gastric discomfort, anorexia and nausea were lowered. In the
meanwhile,improvementingastricemptyingandstabilityof
plasma levodopa level was noted. This may explain why, in6 Evidence-Based Complementary and Alternative Medicine
Table 3: Communications, complications of therapy (within group comparisons).
Time Parameter TCM group (n = 22) P-value Control group (n = 25) P-value
Baseline PDQ-39
Communications 28.03 ± 23.65 23.75 ± 19.77
12 weeks 23.86 ± 19.12 .316 30.67 ± 21.07 .015a
24 weeks 24.24 ± 19.91 .352 29.67 ± 19.85 .043a
Baseline UPDRS IV 4.22 ± 2.69 5.08 ± 3.48
12 weeks 3.36 ± 2.42 .013a 5.08 ± 3.53 1.000
24 weeks 3.22 ± 2.35 .018a 5.12 ± 3.95 .910
Baseline UPDRS IVC 1.09 ± 0.75 0.76 ± 0.83
12 weeks 0.64 ± 0.66 .013a 0.72 ± 0.74 .755
24 weeks 0.50 ± 0.60 .003a 0.68 ± 0.85 .617
aComparison with baseline were statistically signiﬁcant at P<. 05.
Table 4: Communications, complications of therapy (between group comparisons).
Time
(weeks) Parameter TCM group (n = 22) Control group (n = 25) P-value
12 PDQ-39
Communications
−4.17 ± 19.03 6.92 ± 13.27 .024a
24 −3.79 ± 18.67 5.92 ± 13.87 .047a
12 UPDRS IV −0.86 ± 1.49 0.00 ± 0.04 .029a
24 −1.00 ± 1.83 1.44 ± 1.74 .085
12 UPDRS IVC −0.45 ± 0.74 −0.04 ± 0.79 .039a
24 −0.59 ± 0.80 −0.08 ± 0.81 .034a
aComparison with baseline were statistically signiﬁcant at P<. 05.
our study, JWLJZT could alleviate non-motor complications
that are acute side eﬀects of levodopa such as nausea,
vomiting and orthostatic hypotension because these eﬀects
have been shown to be correlated with plasma levodopa
concentrations [25]. Further basic research is required to
explore the underlying mechanisms in detail. Our study was
designed simply to verify the eﬀects, not to elucidate the
mechanisms of these eﬀects of JWLJZT.
Another important observation of our RCT is that
JWLJZT signiﬁcantly aﬀects communications as assessed by
the PDQ-39. Throughout the study, the control group’s
communication scores worsened, while in the treatment
group, improvement was noted at 12 and 24 weeks. Dif-
ferences between these two groups were signiﬁcant. PDQ-
39 measures communication in diﬀerent contexts, including
diﬃculty with speech, feeling unable to communicate prop-
erly and feeling ignored by people. In fact, changes in speech
and voice in PD patients occur in up to 80–90% of cases
and these changes can aﬀect intelligibility, ability and desire
to communicate [26, 27]. In general, individuals feel they
have lost control in communication, are less conﬁdent and
have diﬃculty getting their message across, with subsequent
frustration, feelings of inadequacy and feelings of loss of
independence [28]. In consequence, social isolation may
occur in those patients which greatly reduces their quality
of life and leads to depression [29]. Our ﬁndings thus
provide a new therapeutic approach for those PD patients
with communication diﬃculties. Before our study, Cao and
colleague assessed the eﬀects of a Chinese herbal medicine
“Naokangtai capsule” on 62 cases of PD patients [30]. Their
results showed that patients improved in communications
after 3 months of TCM treatment. Nevertheless, we cannot
exclude the possibility that TCM doctor consultation and
attention may have an impact on these outcomes in our
test group. Such eﬀects have never been studied. Moreover,
communication is sensitive to a variety of life stressors.
Thus, it is hard to discriminate the treatment eﬀects from
those confounding factors. Therefore, the eﬀects on com-
munications observed in our study should contribute to the
ongoing discussion on possible mechanisms of action and
surely deserve consideration in further studies. For example,
further clinical studies using the speciﬁc “Self-Perceived
Communication Competence Scale” (SPCC) would be able
to evaluate the eﬀect of TCM on communication in depth
[31].
In this study, JWLJZT had no eﬀect on Parkinsonian
motor abnormality. Distinct from conventional Western
medicine, individualized treatment according to patient’s
current TCM symptom complex is regarded as a major
feature of TCM. Nevertheless, because of diﬃculties in
standardization and suﬃcient blinding for individualized
treatment, we have not assessed the eﬃcacy of individualized
treatment in this trial. The potential drawback of standard-
ized treatment is a possible loss in the eﬃcacy of the ChineseEvidence-Based Complementary and Alternative Medicine 7
herbal medicine treatments due to a lack of individualized
therapy, as performed in the traditional way. A clinical trial
with proper design is merited to evaluate the eﬃcacy of
individualized herbal treatment in patients with PD [32].
In conclusion, the 11-herb TCM prescription resulted in
signiﬁcant improvement in some non-motor complications
of conventional medicine treatment and communications
abilities in patients with idiopathic PD. Studies of the
biochemical mechanisms by which JWLJZT aﬀects PD could
point the way to further advances and even better clinical
treatment of PD. Also, studies with larger sample sizes are
required which would have increased statistical power and
would be able to better determine if JWLJZT can oﬀer long-
term control of PD and retard the progression of this disease.
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